ClinicalTrials.gg
RecruitingNCT06878417COPEUpdated Jul 16, 2026

Cannabinoids for Osteoarthritis Pain Effectiveness Trial

An interventional study of CBD and THC in Osteoarthritis of Knee and Osteoarthritis Hip, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 40 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.

Planned enrollment
56th of 160
100 · median 63
Started
2026
with 4 others
No phase
100 of 171
19 open now
Primary completion
2026-12
later than 14 of 39 live
Registered
162nd of 171
by date

Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 56th largest by planned enrollment of the 160 interventional ones that give a count, is one of 5 that started in 2026, is one of 100 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 162nd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Osteoarthritis, Knee with a site in Canada, or all of them as a file.
02

Study summary

This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy.

The goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and/or knee osteoarthritis.

Participants will:

  • Take either CBD, THC, or a placebo capsule daily for 8 weeks
  • Complete follow-ups remotely, with no in-person clinic visits required
  • Maintain a diary tracking their study drug usage and any additional pain medications
Read the detailed description

The rationale for this study lies in the significant impact of osteoarthritis (OA) on individuals and society, coupled with the limited effectiveness and potential side effects of current treatments. OA is a prevalent joint disease affecting one in seven Canadians, causing pain, stiffness, and swelling that can significantly disrupt daily life. The economic burden of OA is substantial, costing Canada an estimated $27.5 billion annually. With no cure for OA, current treatments focus on managing pain, the most disabling symptom, and improving physical function. The study addresses a critical gap in knowledge concerning the use of medical cannabis (MC) for OA pain management. Despite a considerable number of Canadians turning to MC for symptom relief, there is a lack of high-quality evidence supporting its effectiveness. This discrepancy between widespread use and insufficient scientific data creates a pressing need for rigorous research. Surveys indicate that approximately 20% of patients with musculoskeletal pain, including OA, have used or are using MC for pain management. Anecdotal evidence suggests effectiveness for some patients, but the lack of robust data leaves important questions unanswered. Key issues include identifying the optimal type of product, the right dose, and the best mode of administration to maximize effectiveness while minimizing side effects. The study is further motivated by the fact that OA patients often face challenges in obtaining clear guidance from healthcare providers regarding MC use due to the scarcity of evidence and concerns about safety. This lack of guidance may result in misinformation, unnecessary expenses, and potential risks for patients. The rationale is strengthened by strong pre-clinical evidence suggesting that cannabinoids, the active compounds in MC, may effectively address OA pain. These compounds act on cannabinoid receptors and other receptors involved in pain and inflammation pathways within the joints. Given the increasing use of MC for OA pain, the lack of high-quality clinical evidence, and the promising pre-clinical data, the study proposes an internal pilot trial to assess the feasibility of a larger, definitive randomized controlled trial (RCT). The internal pilot aims to optimize recruitment and retention strategies before launching a comprehensive investigation into the effectiveness of specific cannabis compounds (CBD and THC) in managing OA pain.

This pilot study is a multicentre, blinded, randomized, placebo-controlled, 3-arm, parallel group (1:1:1 CBD, THC, placebo) internal pilot trial in patients with hip and/or knee osteoarthritis pain. Patients will receive CBD (intervention), THC (intervention), or placebo (control) for 8 weeks.

The primary objective of this internal pilot RCT is to determine the feasibility of a blinded, randomized, placebo-controlled, 3-arm, parallel group trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis. Specifically, this study will determine whether the planned definitive RCT is feasible with respect to patient enrollment, protocol adherence, and data completeness.

This is a decentralized trial whereby participants will be recruited and enrolled from three sites, but all other study-related activities (e.g., shipping of study product, follow-up assessments, etc.) will be conducted by the central coordinating centre (Anesthesia Clinical Trials Unit (ACTU), a clinical research organization located at Toronto General Hospital (TGH)) remotely without requiring patients to attend in-person study visits.

A total of 100 patients will be recruited across all the sites.

Patients from all the recruiting sites will be followed up at the end of weeks 1, 2, 3, 4, 6, and 8 after treatment initiation by the central coordinating centre (ACTU).

During each follow up assessment:

  1. Patients will be assessed for a follow up check-in which includes a brief discussion of treatment efficacy and adverse effects and it will last approximately 10-15 minutes or as long as is needed to address any and all patient concerns. During baseline assessment, the patient receives instructions on starting dose. At 1, 2-, 3- and 4-weeks, the patients will also receive instructions regarding dose titration, as needed.
  2. Patients complete the set of questionnaires which which will be sent to them a day prior of their scheduled follow up. The questionnaires will assess pain severity and interference, physical functioning, sleep quality, anxiety, and depression. In addition, all participants will complete a health-related quality of life questionnaire and rate the overall improvement related to the intervention. The questionnaires will be administered via standardized case report forms in a secure online portal (REDCap).
  3. The patient will also be followed by the blinded research assistant to complete other study related activities (i.e. assessment of study drug compliance, reiterate the importance of a study drug diary and how data should be recorded, confirms capsules count, study drug diary review etc.)

Patients will be unblinded following their 8-week follow-up, which takes place eight weeks after the initiation of treatment. Those choosing to discontinue the investigational products (CBD and THC) will receive support to taper off and will have scheduled follow-ups at the end of the 10th and 12th weeks to monitor the progress of participants during the tapering phase, and for those who choose to continue using cannabis, assistance will be provided to help them secure their own supply of medical cannabis during the next 4-week period.

03

Conditions studied

  • Osteoarthritis of Knee
  • Osteoarthritis Hip

Keywords

  • Medical Cannabis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-80 years
  2. Diagnosed with hip and/or knee osteoarthritis as per the American College of Rheumatology criteria
  3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60
  4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks
  5. Able to self-report, understand and read English or French

Exclusion criteria

Exclusion Criteria:

  1. Hip or knee surgery planned in the coming 4 months,
  2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.),
  3. Planned injection into the affected joint(s) during trial period,
  4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.),
  5. to taking cannabis/cannabinoids,
  6. Used nabilone or nabiximols in the last 30 days,
  7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient ),
  8. A history of diagnosed cannabis use disorder or dependence,
  9. Active substance use disorder,
  10. Current diagnosis of bipolar disorder, major depression, or psychosis,
  11. An uncontrolled medical or major psychiatric disorder,
  12. Currently on warfarin,
  13. Known pregnancy or currently breastfeeding,
  14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs
  15. No fixed address or a plan to change addresses in the coming 4 months,
  16. Known or suspected allergy to palm/coconut oil
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CBD (Cannabidiol)

    Each capsule contains a concentration of 50 mg of Cannabidiol (CBD). Participants will receive CBD for a total duration of 8 weeks.

    Drug: CBD

  • Experimental
    THC (∆9-tetrahydrocannabinol)

    Each capsule contains a concentration of 3 mg of ∆9-tetrahydrocannabinol (THC). Participants will receive THC capsules for a total duration of 8 weeks.

    Drug: THC

  • Placebo comparator
    Placebo

    Participants will receive matching placebo capsules for a total duration of 8 weeks.

    Drug: Placebo

Interventions

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

    Also known as: AVCN319301a

  • DrugDronabinolStudies of DronabinolDronabinol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

    Also known as: AVCN319301b

  • DrugPlacebo

    The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

06

What researchers measure

Primary outcomes

  1. Feasibility outcome: pertaining to the enrollment rate

    Percentage of eligible and interested patients enrolled

    Time frame: Through study completion, an average of 1 year

  2. Feasibility outcome: pertaining to the Protocol adherence

    Percentage of participants with no major protocol deviation (i.e., no concomitant cannabis use or initiation of new OA treatment)

    Time frame: Up to 8 weeks post-treatment

  3. Feasibility outcome: pertaining to data completeness

    Percentage of enrolled participants with complete PROMIS Pain Interference data at 8 weeks

    Time frame: Up to 8 weeks post-treatment

07

Study locations

3 of 3 sites recruiting
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
    • Mary Nasim · ContactMary.nasim@uhn.ca · 1-416-603-5800
    • Dr. Timothy Leroux, MD · Sub investigator
    • Dr. Hance Clarke, MD · Principal investigator
  • Women's College Hospital
    Toronto, Ontario M5S 1B2, Canada
    Recruiting
  • McGill University Health Centre/Montreal General Hospital
    Montreal, Quebec H3G 1A4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 11 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 17, 2025
StartActual
Jan 29, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878417
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Jan 29, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Sonal Thaker
Contact
sonalben.thaker@uhn.ca
1-416-340-4800 ext. 4251
Deep Grewal
Contact
Deep.Grewal@uhn.ca
1-416-340-4800 ext. 4221
Dr. Hance Clarke, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabidiol · Dronabinol

Start the discussion